

## 10th Annual Middle Tennessee Antimicrobial Stewardship Symposium

Jointly Provided by Tennessee Medical Association and  
Belmont University College of Pharmacy & Health Sciences

**Friday, May 1, 2026**

**8:00am-4:00pm (Central)**

**Belmont University, Nashville, TN**

**Target Audience:** Antimicrobial Stewardship Nurses, Pharmacists, Physicians,  
and Infection Preventionists in Tennessee and Surrounding States

**Up to 5.5 contact hours of Live CE Available**

for nurses, pharmacists, and physicians

from ACCME & ACPE for these Knowledge- & Application-based CE Activities

\*Nurses may earn up to 3.0 pharmacotherapeutic contact hours

**1.0 contact hour of BCIDP pharmacy credit available**

**Up to 4.0 contact hours of Home Study CE Credit for the Roundtable Sessions**

Initial Release Date: June 1, 2026

Expiration Date: May 1, 2027

**Deadline to Register: April 20, 2026**

**\$100** - General Registration

**\$75** - Belmont Faculty/Preceptors/Alumni

**\$50** - Students, Residents, Fellows (No CE Credit Awarded)

**\$125** - Late Registration (April 21-27). Registrations will not be accepted after April 27.

**[Register Here](#)**

**Keynote Lecture: Strategies for the Future:**

**Navigating the Rise of Vaccine-Preventable Diseases and Vaccine Hesitancy**

Mary-Margaret A. Fill, MD, MPH; Interim State Epidemiologist; Communicable and Environmental Diseases  
and Emergency Preparedness, Tennessee Department of Health

**Policies** for refunds & cancellations, as well as requirements for successful completion of the CE activities and subsequent awarding of credit, can be found on [page 7](#).

**Disclosures:** Individual speaker disclosures are noted in the presentation details on [pages 2-6](#). Athena Hobbs, planner for this event, is a contracted worker for Cardinal Health. Missy Travis, planner for this event, is a consultant for Georgia Pacific, Laborie, Vitalacy, and TechLab. All relevant financial relationships have been mitigated. No other planners or content reviewers have relevant financial relationships with ineligible companies to disclose.

**Exhibiting Supporters (to-date):** Abbvie, Astellas, Clarametyx, CorMedix Therapeutics, GSK, Innoviva Specialty Therapeutics, Invivyd, Karius, Merck, Paratek Pharma, Shionogi, Society of Infectious Disease Pharmacists (SIDP)

**This project is funded under a Grant Contract** with the State of Tennessee.

### Symposium Learning Objectives

At the end of this symposium, learners should be able to:

- Promote interdisciplinary and interfacility collaboration, as well as support career advancement of members
- Advance the impact of stewardship in facilities through effective communication and collaboration
- Discuss optimization of antimicrobial therapy for certain infections, with consideration for special populations, based on evidence-based medicine
- Identify resources available to assist in the development, maintenance, and enhancement of antimicrobial stewardship programs

**Follow us on social media!**



# Program Agenda

All times are Central


7:15-8:00am

Registration, Exhibitor Engagement & Breakfast (sponsored by Eolas Medical)

8:00-8:15am

Welcome

8:15-9:00am



## Impact of Urbanization, Migration, Climate and Natural Disasters on Infectious Diseases Patterns

(0.75 Contact Hour; UAN: 0863-9999-26-023-L01-P)

**Ben Ryan, Ph.D., MPH, REHS, FRRHHed**; Professor of Public Health and Global Initiatives, Human & Planetary Health Section Lead, Thomas F. Frist, Jr. College of Medicine, Belmont Collaborative for Health Systems Innovation, Belmont University, Nashville, TN  
*Dr. Ryan has no relevant financial relationships to disclose.*

### Learning Objectives:

1. Explain how urbanization, migration, and climate change are driving shifts in disease presence and environmental pathways for antimicrobial resistance (AMR)
2. Specify two stewardship or IPC adjustments for your setting in response to shifts in disease presence and environmental pathways for AMR
3. Use wastewater and vector alerts plus post-flood exposure histories to anticipate new-to-region pathogens and update testing, initial therapy, isolation/cohorting, vaccination review, environmental controls, and AMR-aware stewardship actions

9:00-10:00am



## Updates in the Treatment of Mycobacterium tuberculosis

(1.0 Pharmacotherapeutic Contact Hour; UAN: 0863-9999-26-010-L01-P)

(1.0 contact hour of BCIDP credit. See p. 7 for details)

**Megan Klatt, PharmD, BCIDP, DPLA**; Infectious Diseases/ASP Pharmacist, University of Kansas Medical Center; Lawrence, KS

*Dr. Klatt has no relevant financial relationships to disclose.*

### Learning Objectives:

1. Describe the differences in treatment options for drug-susceptible tuberculosis (TB)
2. Summarize the role of new treatment regimens for drug-resistant TB
3. Identify opportunities and limitations for practical application of the new TB treatment guidelines

10:00-10:20am

Break (sponsored by AbbVie) & Exhibitor Engagement

10:20-11:00am



## The Professional Eras Tour

(0.75 Contact Hour; UAN: 0863-9999-26-017-L99-P)

**Monica V. Mahoney, PharmD, BCPS, BCIDP, FCCP, FIDSA, FIDP, FMSHP**; Clinical Pharmacy Specialist, Infectious Diseases, Outpatient ID/OPAT Clinics, Beth Israel Deaconess Medical Center; Boston, MA

*Dr. Mahoney has no relevant financial relationships to disclose.*

### Learning Objectives:

1. List steps to advance their career outside their employment
2. Identify opportunities for leadership engagement locally, regionally, and nationally

11:00am-12:00pm



## KEYNOTE PRESENTATION

### Strategies for the Future: Navigating the Rise of Vaccine-Preventable Diseases and Vaccine Hesitancy

(1.0 Pharmacotherapeutic Contact Hour; UAN: 0863-9999-26-011-L06-P)

**Mary-Margaret A. Fill, MD, MPH**; Interim State Epidemiologist; Communicable and Environmental Diseases and Emergency Preparedness, Tennessee Department of Health  
*Dr. Fill has no relevant financial relationships to disclose.*

### Learning Objectives:

1. Summarize recent updates and changes in vaccine policy and policy-making procedures.
2. Recall changes in the epidemiology of vaccine preventable disease outbreaks
3. Integrate strategies for effective engagement with patients around vaccine hesitancy

Questions? Email [pharmacyce@belmont.edu](mailto:pharmacyce@belmont.edu)

## **Program Agenda**

**All times are Central**

<b>12:00-1:00pm</b>	<b>Lunch (sponsored by Astellas) &amp; Exhibitor Engagement</b>
<b>1:00-1:30pm</b>	<b>Poster Session &amp; Exhibitor Engagement</b> No CE credit available for Poster Session. Poster details will be listed in the Symposium program that will be available at the Symposium & on the Symposium website in May.
<b>1:30-2:30pm</b>	<b>Panel Discussion</b> (Details are on <a href="#">p. 4</a> ) & <b>Raffle Prize Drawing</b>
<b>2:30-2:45pm</b>	<b>Break &amp; Go to Roundtable Rooms</b>
<b>2:45-3:15pm</b>	<b>Roundtable Session #1</b> (Roundtable topics are listed on <a href="#">pp. 5-6</a> )
<b>3:15-3:20pm</b>	Rotate to Next Roundtable Session
<b>3:20-3:50pm</b>	<b>Roundtable Session #2</b> (Roundtable topics are listed on <a href="#">pp. 5-6</a> )
<b>3:50-4:00pm</b>	Return to Main Conference Room
<b>4:00pm</b>	<b>Closing Remarks &amp; Raffle Prize Drawing</b>

Policies for refunds and cancellations, as well as requirements for successful completion of the CE activities & subsequent awarding of credit, can be found on [page 7](#).

Questions? Email [pharmacyce@belmont.edu](mailto:pharmacyce@belmont.edu)

# PANEL DISCUSSION

1:30-2:30pm (Central)

1.0 Pharmacotherapeutic Contact Hour

## Panel Discussion: Winning Strategies & Missteps: Lessons Learned in Antimicrobial Stewardship

(1.0 Contact Hour; UAN: 0863-9999-26-012-L04-P)

This panel discussion will include examples and advice from antimicrobial stewardship experts from inpatient and outpatient antimicrobial stewardship programs regarding the most effective and least effective interventions for antimicrobial stewardship programs.

### Learning Objectives

1. Summarize effective and ineffective antimicrobial stewardship strategies and identify approaches to avoid or manage common implementation pitfalls
2. Identify challenges and evidence-based solutions for managing antimicrobial stewardship across various patient-care settings
3. Describe opportunities to manage antimicrobial stewardship in patients transitioning from one patient-care setting to another

**Moderator: Alaina DeKerlegand, PharmD, BCIDP**, Pharmacy Coordinator - Infectious Diseases and Antimicrobial Stewardship; PGY2 Internal Medicine Pharmacy Residency Program Coordinator; Methodist University Hospital, Memphis, TN; Assistant Professor, UTHSC, College of Pharmacy

### Panel Discussants

1. **Monica V. Mahoney, PharmD, BCPS, BCIDP, FCCP, FIDSA, FIDP, FMSHP**; Clinical Pharmacy Specialist, Infectious Diseases, Outpatient ID/OPAT Clinics, Beth Israel Deaconess Medical Center; Boston, MA
2. **Nina Monroe, RN, BSN**, Director of Quality and Regulatory Affairs, Tennessee Healthcare Association
3. **Steven VanHook, MD**; Ascension Saint Thomas West, Nashville
4. **Bryan P. White, PharmD, FIDSA, BCIDP**, Infectious Diseases Clinical Pharmacist, PGY2 ID Residency Program Director, University of Oklahoma Medical Center; and Clinical Instructor, Internal Medicine, University of Oklahoma College of Medicine

*Dr. Mahoney is a consultant for BED Biosciences, Cidara Therapeutics, and CSL Seqirus. All relevant financial relationships have been mitigated.*

*Dr. White is on the speakers bureau for Melinta (CorMedix Therapeutics). All relevant financial relationship have been mitigated.*

*Neither Dr. DeKerlegand, Ms. Monroe, nor Dr. VanHook has relevant financial relationship to disclose.*

Questions? Email [pharmacyce@belmont.edu](mailto:pharmacyce@belmont.edu)

# ROUNDTABLE SESSIONS

**2:45-3:15pm & 3:20-3:50pm (Central)**

Learners may attend one (1) roundtable per session.

Capacity is 15 for each roundtable. Please select at least one (1) back-up roundtable per session.

1. **Dialogue & Discussion on the Rise of Vaccine-Preventable Diseases and Vaccine Hesitancy**  
(0.5 Pharmacotherapeutic Contact Hour; UAN: 0863-9999-26-014-H06-P/0863-9999-26-014-L06-P)  
**Mary-Margaret A. Fill, MD, MPH**, Interim State Epidemiologist; Communicable and Environmental Diseases and Emergency Preparedness, Tennessee Department of Health  
*Dr. Fill has no relevant financial relationships to disclose.*  
**Learning Objectives**
  - Recall changes in the epidemiology of vaccine preventable disease outbreaks, particularly in the Southeastern United States (e.g., TN, KY, MS)
  - Identify opportunities to integrate strategies for effective engagement with patients around vaccine hesitancy
2. **Little Patients, Big Differences: Pediatric PK/PD in Infectious Diseases**  
(0.5 Pharmacotherapeutic Contact Hour; UAN: 0863-9999-26-019-H01-P/0863-9999-26-019-L01-P )  
**Katie Olney, PharmD, BCIDP**, Pediatric Infectious Diseases Clinical Pharmacist; Pharmacy Director, Pediatric Antimicrobial Stewardship Program; Program Director, PGY2 Infectious Diseases (Pediatric) Pharmacy Residency, UK HealthCare and Adjunct Assistant Professor, University of Kentucky College of Pharmacy  
*Dr. Olney has no relevant financial relationships to disclose.*  
**Learning Objectives**
  - Identify the unique pharmacokinetic and pharmacodynamic variability in pediatric patients
  - Apply pharmacokinetic/pharmacodynamic principles to optimize antimicrobial regimens while minimizing toxicity
3. **Rx for You? Rx for Two: Antibiotic Safety in Pregnancy**  
(0.5 Pharmacotherapeutic Contact Hour; UAN: 0863-9999-26-021-H05-P/0863-9999-26-021-L05-P )  
**Kayla R. Stover Hielscher, Pharm.D., BCIDP, BCPS, FCCP, FIDSA**, Assistant Dean-Jackson & Professor and Vice Chair of Pharmacy Practice, University of Mississippi School of Pharmacy, and Program Director, PGY2 Infectious Diseases Residency, University of Mississippi Medical Center  
*Dr. Stover has no relevant financial relationships to disclose.*  
**Learning Objectives**
  - Identify therapy for pregnant persons requiring antibiotic treatment
  - Select alternative therapy in pregnant persons with contraindications to first-line therapy
4. **Building a Business Plan for Antimicrobial Stewardship**  
(0.5 Contact Hour; UAN: 0863-9999-26-020-H04-P/0863-9999-26-020-L04-P )  
**Bryan P. White, PharmD, FIDSA, BCIDP**, Infectious Diseases Clinical Pharmacist, PGY2 ID Residency Program Director, University of Oklahoma Medical Center; and Clinical Instructor, Internal Medicine, University of Oklahoma College of Medicine  
*Dr. White has no relevant financial relationship to disclose.*  
**Learning Objectives for Pharmacists**
  - Outline an effective plan for stewardship plan for expansion.
  - Compose a plan for ASP expansion in a format suitable for the C suite (e.g., SBAR, SWOT,).  
**Learning Objectives for Physicians & Nurses**
  - Recognize the need for an effective plan for stewardship expansion.
  - Support the pharmacist lead in developing, presenting, and implementing a business plan for ASP expansion

Questions? Email [pharmacyce@belmont.edu](mailto:pharmacyce@belmont.edu)

## ROUNDTABLE SESSIONS

**2:45-3:15pm & 3:20-3:50pm (Central)**

Learners may attend one (1) roundtable per session.

Capacity is 15 for each roundtable. Please select at least one (1) back-up roundtable per session.

5. **Clinical Decision-Making in *Stenotrophomonas maltophilia* Infections: Navigating Evidence and Uncertainty** (0.5 Pharmacotherapeutic Contact Hour; UAN: 0863-9999-26-024-H01-P/0863-9999-26-024-L01-P)  
**Ashlan J. Kunz Coyne, PharmD, MPH**, Assistant Professor, Pharmacy Practice and Science, University of Kentucky  
*Dr. Kunz Coyne has no relevant financial relationships to disclose.*  
**Learning Objectives**
  - Recognize emerging therapies for *Stenotrophomonas maltophilia* and explain microbiology testing limitations and delays for these therapies
  - Interpret *Stenotrophomonas maltophilia* culture results in monomicrobial and polymicrobial infections
6. **Out with the Old, In with the New: Updated IDSA 2025 Complicated UTI Guidelines** (0.5 Pharmacotherapeutic Contact Hour; UAN: 0863-9999-26-018-H01-P/0863-9999-26-018-L01-P)  
**Caren Azurin, PharmD, BCPS, BCIDP**, Clinical Pharmacy Specialist, Antimicrobial Stewardship, Ascension Saint Thomas Hospital West  
*Dr. Azurin is an advisory board member for Invivyd. All relevant financial relationships have been mitigated.*  
**Learning Objectives**
  - Identify key changes between 2010 and 2025 guidelines
  - Develop treatment plans for diagnosis and managing complicated urinary tract infections
7. **Management of Fever and Leukocytosis by the ID Team** (0.5 Pharmacotherapeutic Contact Hour; UAN: 0863-9999-26-022-H01-P/0863-9999-26-022-L01-P)  
**Megan Uehling, MD**; PGY5 Clinical Fellow, Division of Infectious Diseases, Vanderbilt University Medical Center Department of Medicine. **Advisor: Sara Haddad, MD**, Assistant Professor of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center  
*Neither Dr. Uehling nor Dr. Haddad has relevant financial relationships to disclose.*  
**Learning Objectives for Pharmacists**
  - Assess the role of procalcitonin in determining the need for antibiotics in respiratory infections
  - Identify infectious syndromes where the Staph nasal swab can be used to de-escalate empiric antibiotics
  - Develop a systematic approach to evaluating noninfectious causes of fever, leukocytosis in the ICU
  - Analyze the role of blood cultures in the evaluation of fever, leukocytosis, and different infectious syndromes
8. **Storytelling in antimicrobial stewardship: listening better to difficult conversations** (0.5 Contact Hour; UAN: 0863-9999-26-013-H04-P/0863-9999-26-013-L04-P)  
**Stephen Staggs, MD, MTS**, Associate Professor of Obstetrics & Gynecology, Thomas F. Frist, Jr., College of Medicine, Belmont University  
*Dr. Staggs has no relevant financial relationships to disclose..*  
**Learning Objectives**
  - Identify whether difficult antimicrobial stewardship conversations are primarily driven by trust, emotion, or reasoning.
  - Apply a structured listening approach to respond more effectively in interprofessional antibiotic stewardship encounters.

Questions? Email [pharmacyce@belmont.edu](mailto:pharmacyce@belmont.edu)



## Policies for Refunds and Cancellations

**Refund Policy:** If you need to cancel your registration, please notify us as soon as possible by emailing [pharmacyce@belmont.edu](mailto:pharmacyce@belmont.edu). No refunds will be given for cancellations on or after April 20, 2026. Cancellations prior to April 20, 2026, will receive a refund minus a \$25 processing fee.

**Cancellation Policy:** In the rare event this event is cancelled, registrants will receive a full refund.

## Requirements for Successful Completion of the CE Activities and Awarding of Credit

To be eligible for the awarding of CE credit (contact hours) for any session, each participant **must**:

- [register to attend the Symposium](#);
- attend 100% of the session for which they are seeking contact hours;
- actively participate in the discussions, engagement activities, and live assessment (poll) questions of the session for which they are seeking contact hours; and
- complete the electronic activity evaluation for the session for which they are seeking contact hours.



**Pharmacist Attendees:** Belmont University College of Pharmacy & Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. These knowledge-based activities for pharmacists will provide up to 5.25 contact hours (0.525 CEUs) of live continuing education credit to pharmacists who register to attend the Symposium, attend 100% of a session per time slot, actively participate in the engagement activities of each session attended, and complete the online activity evaluation for each activity attended.

Your CE credits will be submitted to NABP CPE Monitor upon successful completion of the online post-test & activity evaluation. Instructions for completing the evaluation will be emailed to the address you provided to Belmont at the time of registration. Pharmacists with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: <https://nabp.pharmacy/help/>.

To receive credit for your participation, you must include your NABP ePID and Month/Day in your Belmont LMS account profile. Your credit(s) will **not** transfer to CPE Monitor without this information. It is the responsibility of the pharmacist to notify Belmont if their credit isn't posted to CPE Monitor within 5 business days of completing the activity evaluation.



**BCIDP Pharmacy Credit:** The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certified infectious diseases pharmacist (BCIDP) credit. A BCIDP statement of credit will be issued online upon successful completion of a post-test and online evaluation. No partial credit will be given. BCIDP credit must be claimed within 60 days of the live activity date (5/1/26). Participants are responsible for verifying credits were transferred successfully to your BPS profile account before the 60-day deadline. After the 60 day deadline, SIDP will no longer be able to report your credit(s) for this activity. BCIDP credit is available only for the activity titled **"Updates in the Treatment of Mycobacterium tuberculosis."**

**Nurse Attendees:** Each course in this activity is accredited for *AMA PRA Category 1 Credit™*. We recommend that you check with your individual licensing board to confirm acceptance.



**Physician Attendees:** This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the **Tennessee Medical Association** and the **Belmont University College of Pharmacy & Health Sciences**. The **Tennessee Medical Association** is accredited by the ACCME to provide continuing medical education for physicians.

The Tennessee Medical Association designates this live activity for a maximum of **5.5 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Questions? Email [pharmacyce@belmont.edu](mailto:pharmacyce@belmont.edu)